🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Floor Backes

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ORCID: 0000-0002-9225-6913

Also affiliated with The Ohio State University Wexner Medical Center, Ohio State University Hospital, Science History Institute, The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.208Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.07.006

Top 65%

0.208DataRank

Top 65%3 citations

Angeles Alvarez Secord, Steven G. Friedman, Erinn M. Hade, Carson Smitherman, Nikita Bisht +14 more

Papers

Driven by 15 papers — median percentile 35. Top paper: “Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)”.

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.07.006

Top 65%

0.208DataRank

Top 65%3 citations

Angeles Alvarez Secord, Steven G. Friedman, Erinn M. Hade, Carson Smitherman, Nikita Bisht +14 more

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.05.013

N/A

0.104DataRank · unranked

1 citations

Austin Miller, Judith A. Smith, Stuart M. Lichtman, Michael A. Bookman, Carol Aghajanian +17 more

Imaging across the Life Span: Innovations in Imaging and Therapy for Gynecologic Cancer

UNC Libraries(2020)10.17615/k1e3-7g35

N/A

0DataRank · unranked

0 citations

Ahmet S. Ayan, Meng Xu‐Welliver, Nina A. Mayr, Mariam Moshiri, Jun Zhang +6 more

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol

UNC Libraries(2020)10.17615/5jcw-ca69

N/A

0DataRank · unranked

0 citations

David S. Miller, Steven Waggoner, Robert P. Edwards, Saketh R. Guntupalli, Matthew A. Powell +13 more

Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.02.017

N/A

0DataRank · unranked

57 citations

Ashley S. Felix, Marie Plante, Jean‐Pierre Grégoire, Stephanie A. Sullivan, Emma Rossi +7 more

A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition

Cancers(2022)10.3390/cancers14092311

N/A

0DataRank · unranked

17 citations

Shurui Cai, Guozhen Xie, Na Li, Xuetao Bai, Kousalya Lavudi +8 more

High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101040

N/A

0DataRank · unranked

7 citations

David A. Mix Barrington, Morgan Brown, Lynette Gonzalez, Jae Suk Baek, Allison Huffman +10 more

ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression

npj Precision Oncology(2023)10.1038/s41698-023-00411-x

N/A

0DataRank · unranked

18 citations

Ananya Banerjee, Na Li, Yajing Yang, Shurui Cai, Xuetao Bai +11 more

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027

N/A

0DataRank · unranked

20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more

Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.005

N/A

0DataRank · unranked

13 citations

Helen Huang, Bradley J. Monk, Yong-Beom Kim, Moon‐Hong Kim, Paul DiSilvestro +17 more

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Neoplasia(2020)10.1016/j.neo.2020.07.003

N/A

0DataRank · unranked

11 citations

Melodie Parrish, Santosh Bonala, Soo Ngoi, Adrián Gabriel Torres, James Gallagher +10 more

Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma

Gynecologic Oncology Reports(2025)10.1016/j.gore.2025.101782

N/A

0DataRank · unranked

0 citations

Molly Morton, Eric McLaughlin, Anna Gonzalez, Jessica Fulton, Jessica Sciuva +11 more

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6010

N/A

0DataRank · unranked

29 citations

Daniela Matei, Panagiotis A. Konstantinopoulos, Matthew S. Block, Andrea Jewell, Stéphanie Gaillard +15 more